Positive Interim Data Reported from Ph 1/1b PARADIGM-1 trial of ZH9 in NMIBC patients
“There is a clear and urgent need to move beyond BCG. The current treatment burden—requiring up to 18 catheterisations in the first year— detrimentally impacts real-world compliance and patient outcomes,” said Ibs Mahmood, CEO of Prokarium. “Patients deserve a therapy that is not only effective and safe, but also more convenient, and we believe ZH9, reducing this to just 4–5 administrations per year, could be a game changer.”
Share:
More News
“Checkpoint inhibitors have transformed the treatment landscape in many cancers. Unfortunately, the vast majority of colorectal cancer patients with liver metastases remain without an effective immunotherapy option. The liver is a critical immunological bottleneck – a site where anti-tumor immunity is actively suppressed, blunting the benefit of checkpoint blockade,” said
“The ARASEC trial was designed to further evaluate NUBEQA plus ADT in patients with metastatic castration-sensitive prostate cancer using a rigorous and innovative study approach,” said Yesmean Wahdan, Senior Vice President and Head of Medical Affairs, U.S. and North America Pharmaceuticals at Bayer. “Supported by our robust clinical development program,
The sNDA is based on results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15). In EV-304, neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab was compared with standard-of-care neoadjuvant gemcitabine and cisplatin chemotherapy in MIBC patients eligible for cisplatin-containing chemotherapy. In the Event-Free Survival (EFS) analysis, enfortumab vedotin
“CREATE was built as an iterative immune programming platform in which each clinical study informs and strengthens the next, and it is that work that has revealed the breadth of what in vivo immune programming can address,” said Daniel Getts, PhD, Chief Executive Officer of CREATE Medicines. “Our autoimmune and